# Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

> **NCT06562907** · PHASE1 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 134 (estimated)

## Conditions studied

- Weight Management

## Interventions

- **DRUG:** GS-4571
- **DRUG:** Placebo
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT06562907
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-28
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06562907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06562907, "Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06562907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*